Lower Metastasis Risk in Very High-Risk Prostate Cancer With Intensified Treatment
(MedPage Today) -- Men with very high-risk prostate cancer had a significantly lower risk of metastasis when they received darolutamide (Nubeqa) in addition to androgen deprivation therapy (ADT) and radiation therapy (RT), a randomized trial showed...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.